Artiva Biotherapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2019-01-01
- Employees
- 51
- Market Cap
- $248.6M
- Website
- http://www.artivabio.com
Clinical Trials
4
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Conditions
- Refractory Rheumatoid Arthritis (RA)Idiopathic Inflammatory Myopathies (IIMs)Systemic Sclerosis (SSc)Rheumatoid Arthritis (RAIIMMyositisSclerodermaSjogren SyndromeSjogrens Disease
- Interventions
- Drug: Allogeneic NK Cells
- First Posted Date
- 2025-05-25
- Last Posted Date
- 2025-08-15
- Lead Sponsor
- Artiva Biotherapeutics, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT06991114
- Locations
- 🇺🇸
Artiva Investigational Site Aventura, Aventura, Florida, United States
🇺🇸Artiva Investigational Site Plantation, Plantation, Florida, United States
🇺🇸Artiva Investigational Site Charlotte, Charlotte, North Carolina, United States
AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus
- Conditions
- SLELupus Nephritis - WHO Class IIILupus Nephritis - WHO Class IVRefractory Systemic Lupus Erythematosus
- Interventions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2025-08-15
- Lead Sponsor
- Artiva Biotherapeutics, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT06265220
- Locations
- 🇺🇸
Artiva Investigational Site Birmingham, Birmingham, Alabama, United States
🇺🇸Artiva Investigational Site Tucson, Tucson, Arizona, United States
🇺🇸Artiva Investigational Site San Diego, San Diego, California, United States
A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors
- Conditions
- Breast CancerGastric CancerGastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2025-07-30
- Lead Sponsor
- Artiva Biotherapeutics, Inc.
- Target Recruit Count
- 133
- Registration Number
- NCT05678205
- Locations
- 🇺🇸
Oregon Health Science University (OHSU), Portland, Oregon, United States
🇰🇷The Catholic University of Korea, St. Vincent's Hospital, Suwon, Gyeonggi-do, Korea, Republic of
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
- Conditions
- Non Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Artiva Biotherapeutics, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT04673617
- Locations
- 🇺🇸
Artiva Clinical Trial Site, Richmond, Virginia, United States